Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

Early Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Biological: Pelareorep
Drug: Trastuzumab
Drug: Letrozole
Drug: Atezolizumab

First Posted Date: 2019-09-25

Last Posted Date: 2022-08-15

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 26

Registration Number: NCT04102618

Locations: 🇪🇸
Hospital Clínico Universitario de Valencia, Valencia, Spain
🇪🇸
Hospital La Paz, Madrid, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

and more 11 locations

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Phase 1

Terminated

Conditions: Solid Tumor
Extensive-stage Small Cell Lung Cancer

Interventions: Drug: BNT411
Drug: Atezolizumab
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2019-09-24

Last Posted Date: 2024-08-02

Lead Sponsor: BioNTech SE

Target Recruit Count: 55

Registration Number: NCT04101357

Locations: 🇩🇪
University Medical Center Hamburg-Eppendorf - (Recruiting only for part 1B and part 2), Hamburg, Germany
🇩🇪
Universitaetsklinikum Koeln - (Recruiting only for part 1B and part 2), Koeln, Germany
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 9 locations

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Phase 2

Terminated

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2019-09-23

Last Posted Date: 2023-12-26

Lead Sponsor: Duke University

Target Recruit Count: 7

Registration Number: NCT04099836

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Head and Neck Squamous Cell Carcinoma
Melanoma
Solid Tumor

Interventions: Drug: SB 11285
Drug: Atezolizumab

First Posted Date: 2019-09-20

Last Posted Date: 2024-10-31

Lead Sponsor: invoX Pharma Limited

Target Recruit Count: 61

Registration Number: NCT04096638

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2019-09-16

Last Posted Date: 2024-10-24

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 43

Registration Number: NCT04091217

Locations: 🇨🇳
Fujian Provincial Cancer Hospital, Fuzhou City, China
🇨🇳
Beijing Cancer Center; Renal Cancer And Melanoma Department., Beijing City, China
🇨🇳
Zhejiang Cancer Hospital, Zhejiang, China

Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Adult Solid Tumor

Interventions: Biological: SQZ-PBMC-HPV
Drug: Atezolizumab
Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2019-09-10

Last Posted Date: 2023-04-14

Lead Sponsor: SQZ Biotechnologies

Target Recruit Count: 30

Registration Number: NCT04084951

Locations: 🇺🇸
University of Colorado Anschutz Cancer Pavillion, Aurora, Colorado, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States

and more 9 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: Multiple Myeloma
Non-Hodgkin Lymphoma
B-Cell Lymphoma

Interventions: Drug: Tiragolumab
Drug: Daratumumab/rHuPH20
Drug: Rituximab
Drug: Atezolizumab

First Posted Date: 2019-08-05

Last Posted Date: 2023-04-07

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 41

Registration Number: NCT04045028

Locations: 🇺🇸
Virginia Cancer Specialists (Fairfax) - USOR, Fairfax, Virginia, United States
🇺🇸
Clinical Research Alliance, Westbury, New York, United States
🇺🇸
University of Pennsylvania; School of Medicine, Philadelphia, Pennsylvania, United States

and more 11 locations

A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 3

Completed

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Atezolizumab
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2019-07-22

Last Posted Date: 2024-07-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 155

Registration Number: NCT04028050

Locations: 🇮🇹
Azienda Ospedaliera San Camillo Forlanini, Roma, Lazio, Italy
🇮🇹
Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy
🇮🇹
Ospedali Riuniti Di Ancona; Oncology, Ancona, Marche, Italy

and more 22 locations